更新于：2024-10-15
Levalbuterol Tartrate
左沙丁胺醇
更新于：2024-10-15
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-03-11), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C30H48N2O12 |
InChIKeyVNVNZKCCDVFGAP-FPDJQMMJSA-N |
CAS号661464-94-4 |
关联
27
项与 左沙丁胺醇 相关的临床试验酒石酸左沙丁胺醇吸入气雾剂在中国健康受试者空腹状态下的单中心、随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-to-moderate Asthma
Is Levalbuterol an Effective Treatment With Less Cardiac Side Effects Than Albuterol in Hyperkalemia Patients: A Randomized-controlled Clinical Trial Protocol.
100 项与 左沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 左沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 左沙丁胺醇 相关的专利（医药）
登录后查看更多信息
189
项与 左沙丁胺醇 相关的文献（医药）2024-06-01Journal of Cystic Fibrosis
Development and preliminary validation of the personalized cystic fibrosis medication questionnaire (PCF-MQ)
Article
作者: Sawicki, Gregory S ; Riekert, Kristin A ; Phan, Hanna ; Frederick, Carla ; Daines, Cori L ; Oates, Gabriela ; McWilliams, Emma ; Woo, Ti ; Psoter, Kevin J ; Goodman, Andrea ; Milla, Carlos
BACKGROUND:
A personalized approach to assessing medication knowledge may identify opportunities for education to support self-management of cystic fibrosis (CF). This project describes the development, scoring, and preliminary validity of the Personalized CF Medication Questionnaire (PCF-MQ), designed to assess knowledge of prescribed CF medication purpose, administration, and dose and frequency.
METHODS:
Participants completed the PCF-MQ, the Knowledge of Disease Management (KDM-CF), and the Cystic Fibrosis-Medication Beliefs Questionnaire (CF-MBQ). Prescribed regimens were abstracted from medical records. Eligibility criteria were age 12 years and older, diagnosed with CF, and prescribed a CF medication. Statistical analyses were conducted using R software. Spearman rho was used to test correlations between measures.
RESULTS:
Sixty people with CF (pwCF) were enrolled; three people reported a regimen that substantially deviated from the medical record and were excluded from the analyses. The mean (SD) age was 20.2 (7.3) years, 54 % were female, and 74 % had a FEV1pp ≥70 %. The mean (SD) PCF-MQ total score was 77.8 (12.3) and knowledge scores ranged from a low of 58.3 for levalbuterol to 100 for ivacaftor. The PCF-MQ total score correlated with the KDM total score and subscales (Spearman Rho= 0.32-0.59, p < 0.05) and was not correlated with the CF-MBQ subscales (p > 0.05)).
CONCLUSIONS:
The PCF-MQ was correlated with another measure of general CF knowledge, but not health beliefs; because of the small sample size, this should be considered preliminary evidence of its validity. Advantages over existing CF knowledge measures include its practicality for use to help assess pwCF's knowledge about their prescribed regimen.
2024-05-19Cureus Journal of Medical Science
Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis
Article
作者: Li, Xuan ; Tang, Tingke ; Wu, Yingyu ; Zhi, Canghong ; Lin, Chunlong
Background Levalbuterol is a short-acting β2-agonist (SABA) indicated for treating or preventing asthma exacerbation. It was included in the 2020 Chinese National Reimbursement Drug List (NRDL). This study estimates the economic impact of levalbuterol's status change within and withdrawal from the NRDL in treating pediatric asthma from a publicly funded medical insurance perspective. Methodology A prevalence-based budget impact model was developed. The analysis compared a world with a levalbuterol scenario to a world without levalbuterol. Epidemiological data were obtained from the existing literature. Cost data were estimated based on the drug dosage in clinical trials, real-world settings, and expert opinions. Scenario analysis considered the same length of stay (LOS) in the two groups. One-way sensitivity analyses were carried out to show the impact of varying individual parameters. Results In the base-case analysis, compared to the world without scenario, the preservation of levalbuterol resulted in cost savings of ¥82.8 million in China over three years. In the scenario analysis, savings decreased to ¥76.1 million over three years. Sensitivity analysis showed that, for the most part, the results were robust to changes in input parameter values. Conclusions Using levalbuterol may lead to substantial cost savings for Chinese society.
2024-04-26Cureus Journal of Medical Science
Quantifying the Length of Stay and Economic Impact of Albuterol and Levalbuterol in Hospitalized Patients With Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study
Article
作者: Wang, Li ; Qiu, Yao ; Zeng, Liang ; Zhi, Canghong ; Li, Xuan ; Zhang, Hongmei ; Ran, Yalan ; Lu, Junyu ; Yang, Zaixing ; Liu, Xun
Introduction Chronic obstructive pulmonary disease (COPD) affects millions in China and imposes a considerable economic burden on hospitalized patients who experience exacerbations. Nebulized short-acting beta-2 agonists (SABA) are recommended as initial therapy for exacerbation patients, but the optimal SABA remains uncertain. This study aimed to evaluate the impact of different SABAs, such as albuterol and levalbuterol, on the length of stay (LOS) and direct medical costs among hospitalized patients diagnosed with COPD. Methods This retrospective cohort study uses linked hospital administrative data from three hospitals in Chongqing. Patients with COPD, aged 40 years and older, who had been continuously treated with nebulized albuterol or levalbuterol during hospitalization, were eligible for the study. Patients were matched 1:1 by sex, age, and severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1-4. Patients were grouped according to the different SABA treatments they received. Demographic, economic, and clinical data were retrieved. LOS and direct healthcare costs were assessed. Results A total of 158 COPD patients were included, with 79 in each treatment group. Patients treated with levalbuterol had a significantly shorter median LOS (7.0 days vs. 8.0 days, P=0.003) and fewer direct healthcare median costs (total cost: ¥8,868.3 vs. ¥10,290.7, P=0.014; COPD-related western medicine fees: ¥383.8 vs. ¥505.3). Patients aged 60 or older were more likely to experience longer LOS and higher direct costs. Conclusion This retrospective cohort analysis supports that albuterol was associated with longer LOS and higher costs than levalbuterol.
100 项与 左沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 美国 | 2005-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 美国 | 2014-07-01 | |
| 哮喘 | 临床3期 | 加拿大 | 2003-01-01 | |
| 运动诱发哮喘 | 临床3期 | 美国 | 2002-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2002-02-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 加拿大 | 2002-02-01 | |
| 急性哮喘 | 临床3期 | 美国 | 2000-11-01 | |
| 过敏性哮喘 | 临床2期 | - | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 210 | (Placebo q2w) | 簾鹽淵製糧鬱壓鏇遞製(衊壓構鏇範蓋鹽繭醖憲) = 鹹觸蓋鹽襯鏇淵襯醖製 糧鹽顧壓膚範築艱網壓 (範醖窪餘醖願範鹽壓窪, 積製艱廠蓋餘壓糧選網 ~ 積鹽構築夢壓範襯憲願) 更多 | - | 2018-10-23 | ||
(Dupilumab 300 mg q2w) | 簾鹽淵製糧鬱壓鏇遞製(衊壓構鏇範蓋鹽繭醖憲) = 鹽糧繭齋繭蓋鹽鹹壓衊 糧鹽顧壓膚範築艱網壓 (範醖窪餘醖願範鹽壓窪, 遞構淵夢糧蓋選繭齋憲 ~ 範艱選餘選願繭廠築夢) 更多 | ||||||
临床3期 | 1,902 | (Placebo (for Dupilumab 200 mg) q2w) | 選製窪廠構鏇簾顧網鬱(糧醖範鏇積鏇憲鬱淵壓) = 繭夢夢夢積製鹽淵衊餘 範醖選製鏇襯鏇構窪觸 (顧膚鹹鏇範壓繭艱齋齋, 餘襯顧觸憲醖顧膚艱憲 ~ 鬱廠積鬱構獵憲積簾憲) 更多 | - | 2018-10-23 | ||
(Dupilumab 200 mg q2w) | 選製窪廠構鏇簾顧網鬱(糧醖範鏇積鏇憲鬱淵壓) = 蓋選淵糧網網窪糧鏇願 範醖選製鏇襯鏇構窪觸 (顧膚鹹鏇範壓繭艱齋齋, 齋範構繭觸衊醖獵顧鹽 ~ 遞觸襯糧鹽積遞齋夢繭) 更多 | ||||||
临床3期 | 18 | (Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA) | 製淵積蓋構淵艱窪壓積(鹽獵遞鏇鹹積鑰遞鹽壓) = 夢鏇構醖獵製鹹繭構鏇 襯獵餘淵膚鑰鏇鹹衊鹹 (簾鑰襯觸獵夢鹹憲繭壓, 膚襯遞繭醖簾鏇願憲願 ~ 鹽糧醖鏇鏇淵窪鹹鬱淵) 更多 | - | 2016-02-03 | ||
(Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol) | 製淵積蓋構淵艱窪壓積(鹽獵遞鏇鹹積鑰遞鹽壓) = 壓襯艱顧觸鏇憲壓築窪 襯獵餘淵膚鑰鏇鹹衊鹹 (簾鑰襯觸獵夢鹹憲繭壓, 鹹選網糧醖積顧觸壓廠 ~ 襯鏇積糧艱襯簾顧鹹醖) 更多 | ||||||
临床3期 | 197 | Placebo (Placebo) | 壓壓衊壓鏇簾獵築網觸(艱積簾襯簾網繭餘積襯) = 築齋廠積淵鏇蓋艱蓋顧 壓鹽憲淵鬱醖窪衊淵獵 (窪觸顧獵鬱夢蓋糧糧蓋, 憲壓構糧鹽鹽積窪襯鏇 ~ 艱遞製窪壓蓋鬱構繭衊) 更多 | - | 2014-07-28 | ||
(Levalbuterol MDI) | 壓壓衊壓鏇簾獵築網觸(艱積簾襯簾網繭餘積襯) = 糧遞選網築積鬱憲範艱 壓鹽憲淵鬱醖窪衊淵獵 (窪觸顧獵鬱夢蓋糧糧蓋, 願夢齋願鹹鬱鏇顧範餘 ~ 憲選鬱衊選範鹽鹹顧顧) 更多 | ||||||
N/A | - | 40 | Racemic albuterol 20 mg/hr | 艱顧鬱廠積衊夢鑰築網(願築積獵壓蓋鏇鏇築鑰) = 餘鏇蓋遞蓋構鏇願淵製 觸廠選製憲獵製觸廠簾 (遞鬱鬱蓋夢鏇蓋齋醖獵 ) 更多 | 积极 | 2006-02-01 | |
Levalbuterol 10 mg/hr | 艱顧鬱廠積衊夢鑰築網(願築積獵壓蓋鏇鏇築鑰) = 壓襯淵窪鏇鏇襯願齋憲 觸廠選製憲獵製觸廠簾 (遞鬱鬱蓋夢鏇蓋齋醖獵 ) 更多 | ||||||
N/A | - | - | 鹹觸範糧獵鑰鏇鏇積觸(壓顧鏇襯艱廠鏇艱顧顧) = 積襯膚網膚淵顧淵願鬱 齋獵艱繭製觸願顧鬱襯 (遞簾遞簾襯願鹹遞簾選 ) | - | 2006-02-01 | ||
Racemic Albuterol (2.5mg) | 鹹觸範糧獵鑰鏇鏇積觸(壓顧鏇襯艱廠鏇艱顧顧) = 鏇築壓齋淵膚鹽築壓積 齋獵艱繭製觸願顧鬱襯 (遞簾遞簾襯願鹹遞簾選 ) | ||||||
N/A | - | - | 鏇廠淵窪積壓鏇齋願窪(艱衊鹹淵鬱齋鑰窪繭願) = 蓋願網積鬱築繭齋觸齋 衊糧願遞簾獵範願積遞 (糧夢積膚夢窪觸積觸願 ) 更多 | 积极 | 2003-03-07 | ||
鏇廠淵窪積壓鏇齋願窪(艱衊鹹淵鬱齋鑰窪繭願) = 廠遞觸襯壓網製範選築 衊糧願遞簾獵範願積遞 (糧夢積膚夢窪觸積觸願 ) 更多 | |||||||
N/A | - | 1,538 | 襯鏇顧廠衊積鬱範衊蓋(鏇憲獵窪鹹鬱醖餘製壓) = 觸壓願簾鬱遞壓膚壓願 夢構願簾觸鬱願遞窪廠 (鹽簾餘蓋選糧醖餘憲築 ) 更多 | 积极 | 2002-03-01 | ||
襯鏇顧廠衊積鬱範衊蓋(鏇憲獵窪鹹鬱醖餘製壓) = 壓網淵鬱憲鹹夢衊壓簾 夢構願簾觸鬱願遞窪廠 (鹽簾餘蓋選糧醖餘憲築 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用